Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LLY 
Eli Lilly and Company (LLY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: LLY (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 77.97% | Avg. Invested days 57 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 738.60B USD | Price to earnings Ratio 70.42 | 1Y Target Price 1010.47 |
Price to earnings Ratio 70.42 | 1Y Target Price 1010.47 | ||
Volume (30-day avg) 3530972 | Beta 0.34 | 52 Weeks Range 710.18 - 969.25 | Updated Date 03/30/2025 |
52 Weeks Range 710.18 - 969.25 | Updated Date 03/30/2025 | ||
Dividends yield (FY) 0.73% | Basic EPS (TTM) 11.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 23.51% | Operating Margin (TTM) 42.84% |
Management Effectiveness
Return on Assets (TTM) 15.33% | Return on Equity (TTM) 84.26% |
Valuation
Trailing PE 70.42 | Forward PE 35.97 | Enterprise Value 768826056589 | Price to Sales(TTM) 16.4 |
Enterprise Value 768826056589 | Price to Sales(TTM) 16.4 | ||
Enterprise Value to Revenue 17.07 | Enterprise Value to EBITDA 50.49 | Shares Outstanding 897988992 | Shares Floating 895942537 |
Shares Outstanding 897988992 | Shares Floating 895942537 | ||
Percent Insiders 0.17 | Percent Institutions 83.58 |
Analyst Ratings
Rating 4.25 | Target Price 984.05 | Buy 6 | Strong Buy 15 |
Buy 6 | Strong Buy 15 | ||
Hold 6 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Eli Lilly and Company
Company Overview
History and Background
Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana. Initially focused on manufacturing quality medications, it has grown into a global pharmaceutical leader through innovation and strategic expansion.
Core Business Areas
- Human Pharmaceutical Products: Discovers, develops, manufactures, and markets human pharmaceutical products. It is the company's largest segment.
- Animal Health: Develops and markets products for companion animals and livestock.
Leadership and Structure
The leadership team is headed by David A. Ricks (Chairman and CEO). Eli Lilly operates with a functional organizational structure divided into research, development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Mounjaro (tirzepatide): A GLP-1 receptor agonist and GIP receptor agonist used for the treatment of type 2 diabetes. Gained traction due to weight loss benefits. Competitors include Novo Nordisk's Ozempic and Wegovy. Revenue was $5.16 billion in 2023.
- Trulicity (dulaglutide): A GLP-1 receptor agonist for treating type 2 diabetes. Competitors include Ozempic. Revenue was $7.43 billion in 2023.
- Verzenio (abemaciclib): A CDK4/6 inhibitor used to treat certain types of breast cancer. Competitors include Pfizer's Ibrance and Novartis' Kisqali. Revenue was $3.98 billion in 2023.
- Emgality (galcanezumab): A calcitonin gene-related peptide (CGRP) antagonist used to treat migraine. Competitors include Amgen's Aimovig and Teva's Ajovy. Revenue was $725.9 million in 2023.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory oversight, and intense competition. It is currently experiencing growth driven by aging populations and increased healthcare spending.
Positioning
Eli Lilly is a leading player in the pharmaceutical industry, particularly in diabetes, oncology, and immunology. Its competitive advantages include a strong pipeline of innovative drugs and a global presence.
Total Addressable Market (TAM)
The global pharmaceuticals market is valued at over $1.4 trillion. Eli Lilly is well-positioned to capture a significant share of this market with its robust pipeline and established product portfolio.
Upturn SWOT Analysis
Strengths
- Strong drug pipeline
- Established global presence
- Expertise in key therapeutic areas
- Robust research and development capabilities
- Financial stability
Weaknesses
- Reliance on key products
- Exposure to patent expirations
- High R&D costs
- Dependence on regulatory approvals
- Price Pressure on Generic Drugs
Opportunities
- Expansion into new therapeutic areas
- Growth in emerging markets
- Strategic acquisitions and partnerships
- Development of personalized medicine
- Leveraging digital health technologies
Threats
- Increasing competition
- Generic drug erosion
- Regulatory changes
- Pricing pressures
- Economic downturns
Competitors and Market Share
Key Competitors
- NVO
- MRK
- PFE
- ABBV
- BMY
Competitive Landscape
Eli Lilly competes with other large pharmaceutical companies on the basis of product innovation, pricing, and market access. It has a competitive advantage in certain therapeutic areas, such as diabetes and oncology.
Major Acquisitions
Sigilon Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 309
- Strategic Rationale: Expanded Lilly's presence in cell therapy and diabetes treatments.
DICE Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 1400
- Strategic Rationale: DICE's oral IL-17 inhibitors complement Lilly's existing immunology portfolio
Growth Trajectory and Initiatives
Historical Growth: Eli Lilly has experienced moderate revenue growth over the past decade, driven by product launches and acquisitions.
Future Projections: Analysts project continued revenue and earnings growth for Eli Lilly, driven by its strong pipeline and strategic initiatives. Expected Revenue growth between 2024 and 2026 is expected to be between 10 and 12 percent.
Recent Initiatives: Recent initiatives include the launch of new products (Mounjaro), expansion into emerging markets, and strategic acquisitions.
Summary
Eli Lilly shows promise due to its strong drug pipeline and financial performance. Its innovative diabetes and weight management drugs, like Mounjaro, drive growth. Patent expirations and competition are the main concerns. Continued investment in R&D will be critical for sustained success. The company needs to look out for pricing pressures as well as regulatory changes.
Similar Companies
- NVO
- MRK
- PFE
- ABBV
- BMY
Sources and Disclaimers
Data Sources:
- Eli Lilly Investor Relations
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and analyst estimates, which are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eli Lilly and Company
Exchange NYSE | Headquaters Indianapolis, IN, United States | ||
IPO Launch date 1978-01-13 | Chairman, CEO & President Mr. David A. Ricks | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 47000 | Website https://www.lilly.com |
Full time employees 47000 | Website https://www.lilly.com | ||
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.